Phase I Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase I Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Feb 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
    • 21 Jan 2011 Planned end date changed from Jan 2011 to Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top